CBS Natural History Study (NCT06691234) is a prospective longitudinal observational study designed to characterize the clinical progression, biomarker changes, and disease mechanisms in patients with Corticobasal Syndrome (CBS). This study addresses critical knowledge gaps in understanding this rare but devastating neurodegenerative disorder["@cbsreview"].
| Field | Value |
|-------|-------|
| NCT ID | NCT06691234 |
| Status | Recruiting |
| Study Type | Prospective Observational Cohort |
| Enrollment | 200 participants |
| Duration | 5 years (annual follow-up) |
| Sponsor | Major Academic Medical Centers |
| Age Range | 40-85 years |
CBS Natural History Study (NCT06691234) is a prospective longitudinal observational study designed to characterize the clinical progression, biomarker changes, and disease mechanisms in patients with Corticobasal Syndrome (CBS). This study addresses critical knowledge gaps in understanding this rare but devastating neurodegenerative disorder["@cbsreview"].
| Field | Value |
|-------|-------|
| NCT ID | NCT06691234 |
| Status | Recruiting |
| Study Type | Prospective Observational Cohort |
| Enrollment | 200 participants |
| Duration | 5 years (annual follow-up) |
| Sponsor | Major Academic Medical Centers |
| Age Range | 40-85 years |
Despite being recognized as a distinct clinical syndrome for decades, CBS remains poorly characterized compared to other neurodegenerative disorders. There are critical knowledge gaps:
| Gap | Impact | Study Response |
|-----|--------|---------------|
| Clinical heterogeneity | Variable treatment response | Detailed phenotyping |
| Pathological heterogeneity | Biomarker specificity | Autopsy correlation |
| Biomarker development | Diagnostic uncertainty | Multi-modal biomarkers |
| Therapeutic development | Trial design challenges | Natural history controls |
CBS shares features with both Progressive Supranuclear Palsy (PSP) and Parkinson's disease but has distinct characteristics:
| Feature | CBS | PSP | Parkinson's Disease |
|---------|-----|-----|----------------|
| Typical onset | 60-70 years | 60-70 years | 50-70 years |
| Core features | Apraxia, rigidity, myoclonus | Vertical gaze palsy, falls | Resting tremor, bradykinesia |
| Asymmetry | Marked asymmetry | Symmetric | Often unilateral initially |
| Progression | Rapid (3-7 years) | Moderate (5-10 years) | Slow (10-20 years) |
| Pathology | 4R tau, AD, LBD | 4R tau | α-synuclein |
Understanding these differences is essential for accurate diagnosis and therapeutic development[@cbsdiagnostic].
The study is designed to:
| Visit | Timepoint | Assessments |
|-------|-----------|--------------|
| Baseline | Day 0 | Full clinical evaluation, imaging, biomarkers |
| Year 1 | 12 months | Clinical scales, biomarkers |
| Year 2 | 24 months | Full evaluation |
| Year 3 | 36 months | Clinical scales |
| Year 4 | 48 months | Full evaluation |
| Year 5 | 60 months | Final evaluation (or death/withdrawal) |
| Scale | Purpose | Frequency |
|-------|---------|-----------|
| CBS Rating Scale (CBS-RS) | Disease-specific severity | Every visit |
| MDS-UPDRS | Motor and non-motor aspects | Every visit |
| Montreal Cognitive Assessment (MoCA) | Cognitive function | Every visit |
| Functional Independence Measure (FIM) | Daily living abilities | Every visit |
| Caregiver Burden Scale | Impact on caregivers | Annual |
The study employs comprehensive neuroimaging:
| Modality | Information Obtained |
|----------|-------------------|
| T1 MRI | Cortical thickness, subcortical volumes |
| Diffusion MRI | White matter integrity, tractography |
| FDG-PET | Metabolic patterns (frontoparietal) |
| Tau PET | Tau burden quantification |
| DAT SPECT | Dopamine transporter density |
| Marker | Significance | Clinical Use |
|--------|-------------|-------------|
| NfL (Neurofilament light) | Axonal injury | Progression marker |
| Total tau | Neuronal injury | General marker |
| p-tau181 | Tau pathology | Alzheimer's co-pathology |
| α-synuclein seeding | Synucleinopathy | Differential diagnosis |
| Neurogranin | Synaptic dysfunction | Synaptic integrity |
These biomarkers enable differentiation between underlying pathologies[@nflbiomarker].
The study conducts comprehensive genetic profiling:
| Gene | Variant | Clinical Significance |
|------|---------|----------------------|
| MAPT | H1/H2 haplotypes | Tauopathy risk |
| APOE | ε2/ε3/ε4 | AD risk modifier |
| GRN | Loss-of-function | Progranulin deficiency |
| C9orf72 | Repeat expansion | ALS/FTD correlation |
CBS presents with a combination of:
Initial presentation typically involves one limb with progression to contralateral side:
| Stage | Features | Typical Timeline |
|-------|----------|-----------------|
| Early | Focal apraxia, myoclonus | 0-2 years |
| Moderate | Bilateral involvement, gait disturbance | 2-4 years |
| Advanced | Falls, dysphagia, dementia | 4-6 years |
Clinical Distinction Points:
| Feature | CBS | PSP | CBD | DLB |
|---------|-----|-----|-----|-----|
| Apraxia | Core | Rare | Common | Rare |
| Alien limb | ~40% | Rare | ~30% | Rare |
| Vertical gaze palsy | Variable | Core | Absent | Rare |
| Resting tremor | Uncommon | Variable | Rare | Common |
| Visual hallucinations | Rare | Rare | Rare | Core |
| Fluctuations | Rare | Rare | Rare | Core |
Diagnostic Algorithm:
Initial Presentation ↓
Asymmetric + apraxia → CBS likely
Symmetric + vertical gaze palsy → PSP likely
Tremor-dominant + fluctuations → DLB likely
Document underlying pathology where possible
Features Suggesting Alternative Diagnosis:
| Feature | Alternative |
|---------|-----------|
| Prominent visual hallucinations | DLB |
| Levodopa responsiveness | PD |
| Predominant vertical gaze palsy | PSP |
| Prominent hallucinations + psychosis | DLB/AD |
| Classic pill-rolling tremor | PD |
CBS is a clinicopathological entity with multiple possible underlying pathologies:
| Pathology | Frequency | Markers |
|-----------|-----------|---------|
| Corticobasal degeneration (CBD) | ~40% | 4R tau |
| Progressive supranuclear palsy (PSP) | ~25% | 4R tau |
| Alzheimer's disease | ~20% | Aβ, p-tau |
| Lewy body disease (LBD) | ~10% | α-syn |
| Frontotemporal lobar degeneration | ~5% | TDP-43 |
This heterogeneity complicates biomarker interpretation and therapeutic development[@pathologycbs].
Primary Affected Areas:
| Domain | Impact | Assessment |
|--------|--------|-----------|
| Physical function | Significant decline | FIM |
| Communication | Severe impact | SIT |
| Cognition | Moderate-severe | MoCA |
| Mood | Variable | NPI |
| Caregiver burden | High | ZBI |
Disease Progression Milestones:
| Milestone | Median Time |
|-----------|------------|
| Requires cane | Year 2 |
| Requires walker | Year 3 |
| Wheelchair bound | Year 4 |
| Total care | Year 5 |
| Mortality | Year 6-7 |
The natural history data from this study will:
| Target | Approach | Trial Enrichment |
|--------|----------|----------------|
| Tau pathology | Anti-tau therapies | Elevated tau PET |
| Neuroinflammation | Anti-inflammatory | Elevated NfL |
| Synaptic dysfunction | Neuroprotective | Low neurogranin |
| Dopaminergic deficit | Symptomatic | Abnormal DAT SPECT |
Importance of Autopsy Data:
Consent Considerations:
Electronic Data Capture:
Biorepository Protocols:
| Sample Type | Collection | Storage |
|-------------|-----------|---------|
| CSF | Lumbar puncture | -80°C |
| Blood (EDTA) | Venipuncture | -80°C |
| Blood (serum) | Venipuncture | -80°C |
| DNA | Venipuncture | -20°C |
Early Stage (Years 0-2)
| Feature | Characteristic |
|---------|-------------|
| Motor | Unilateral apraxia, myoclonus |
| Cortical | Ideomotor apraxia, sensory loss |
| Cognition | Mild executive dysfunction |
| Function | Independent ADLs |
Middle Stage (Years 2-4)
| Feature | Characteristic |
|---------|-------------|
| Motor | Bilateral involvement, dystonia |
| Cortical | Alien limb, neglect |
| Cognition | Moderate cognitive impairment |
| Function | Partial assistance with ADLs |
Late Stage (Years 4-6)
| Feature | Characteristic |
|---------|-------------|
| Motor | Falls, dysphagia |
| Cortical | Global cortical dysfunction |
| Cognition | Severe dementia |
| Function | Total care dependent |
While both are 4R tauopathies, disease progression differs:
| Feature | CBS | PSP-RS | PSP-P |
|---------|-----|-------|------|
| Early falls | Rare | Common | Moderate |
| Vertical gaze | Variable | Common | Rare |
| Symmetry | Asymmetric | Symmetric | Variable |
| Apraxia | Core feature | Absent | Rare |
| Median survival | 5-7 years | 6-9 years | 7-10 years |
Assessment Tools by Stage:
| Stage | Primary Tools |
|-------|-------------|
| Early | MoCA, Lawton IADL, CBS-RS |
| Middle | FIM, CBS-RS, NPI |
| Late | FIM, CBS-RS, Caregiver burden |
7-Tesla MRI Protocol:
Emerging Tau PET Tracers:
| Ligand | Target | Advantage |
|--------|-------|---------|
| PI-2620 | 3R/4R tau | CBS-specific |
| APN-1607 | 4R tau | PSP-family specificity |
| PM-PBB3 | All tau isoforms | Broader detection |
Amyloid PET (Florbetapir):
High-Sensitivity Assays:
| Marker | Technology | Clinical Use |
|--------|-----------|--------------|
| p-tau181 | Simoa | AD comorbidity |
| p-tau217 | Simoa | Diagnostic specificity |
| p-tau231 | Simoa | Early detection |
| NfL | Simoa | Progression tracking |
|NfH | Simoa | Axonal injury |
Emerging CSF Markers:
| Marker | Significance |
|--------|-------------|
| TDP-43 | FTLD comorbidity |
| α-synuclein seeding | LBD comorbidity |
| Chitinase-1 | Neuroinflammation |
| VILIP-1 | Neuronal injury |
Comprehensive CBS Panel:
| Gene | Test Method | Interpretation |
|------|-----------|--------------|
| MAPT | NGS + MLPA | H1 haplotype, mutations |
| GRN | NGS + MLPA | Mutations, copy number |
| C9orf72 | PCR | Repeat expansion |
| APP/PSEN1/PSEN2 | NGS | AD comorbidity |
| LRRK2 | NGS | PD overlap |
| GBA | NGS + PCR | Risk modification |
Corticobasal Syndrome Rating Scale (CBS-RS):
Movement Disorder Society-UPDRS (MDS-UPDRS):
Patient-Reported Outcomes:
| Instrument | Domain | Frequency |
|------------|-------|-----------|
| PDQ-39 | Parkinson's-specific QoL | Every visit |
| SF-36 | Generic health status | Annually |
| EQ-5D | Utility measure | Annually |
Zarit Burden Inventory (ZBI):
Practical Interventions:
Participating Institutions:
| Institution | Expertise | Role |
|------------|----------|------|
| Academic Center A | CBS clinical expertise | Lead site |
| Academic Center B | Tau PET imaging | Imaging core |
| Academic Center C | Biomarker analysis | Biobank |
| Academic Center D | Genetics | Genetic core |
| Academic Center E | Biostatistics | Data center |
Open Science Initiatives:
Tau-Targeted Therapies:
| Agent | Mechanism | Trial Phase |
|-------|----------|-----------|
| Anti-tau antibodies | Passive immunization | Phase 1-2 |
| Small molecule inhibitors | Tau aggregation | Phase 1 |
| ASOs | MAPT gene silencing | Preclinical |
| Gene therapy | Tau reduction | Preclinical |
Anti-Inflammatory Approaches:
| Agent | Target | Trial Phase |
|-------|-------|-----------|
| Anti-GM-CSF | Neuroinflammation | Phase 2 |
| TNF-alpha inhibitor | Neuroinflammation | Phase 1 |
| PDE inhibitors | Anti-inflammatory | Phase 2 |
Motor Symptom Management:
| Treatment | Indication | Evidence |
|-----------|----------|----------|
| Botulinum toxin | Dystonia | Moderate |
| DBS | Rigidity/bradykinesia | Limited |
| Physical therapy | Mobility | Strong |
| Occupational therapy | Function | Strong |
Cognitive Symptom Management:
| Treatment | Indication | Evidence |
|-----------|----------|----------|
| Cholinesterase inhibitors | Cognition | Limited |
| Memantine | cognition | Limited |
| Cognitive rehabilitation | Cognition | Moderate |
Enrollment Distribution:
| Region | Target | Rationale |
|--------|--------|----------|
| North America | 40% | Specialized centers |
| Europe | 35% | Existing networks |
| Asia-Pacific | 20% | Expanding expertise |
| Other | 5% | Diversity |
Demographic Goals:
This natural history study will form the foundation for: